Les anticorps monoclonaux dans le traitement du cancer, Forum Med Suisse, vol.8, issue.9, pp.160-165, 2008. ,
Continuous cultures of fused cells secreting antibody of predefined specificity, Nature, vol.3, issue.5517, pp.495-502, 1975. ,
DOI : 10.1038/256495a0
Les anticorps monoclonaux th??rapeutiques, Annales Pharmaceutiques Fran??aises, vol.64, issue.5, pp.308-311, 2006. ,
DOI : 10.1016/S0003-4509(06)75323-8
Anticorps monoclonaux ?? usage th??rapeutique : sp??cificit??s du d??veloppement clinique, ??valuation par les agences, suivi de la tol??rance ?? long terme, Th??rapie, vol.67, issue.4, pp.319-327, 2012. ,
DOI : 10.2515/therapie/2012043
Anticorps monoclonaux à usage thérapeutique en hémato-oncologie : généralités, Rev Med Liège, vol.64, pp.5-6, 2009. ,
Thèse : Effet thérapeutique du cétuximab administré par aérosol dans un modèle animal de tumeur broncho-pulmonaire. Importance du récepteur FcRn dans la réponse anti-tumorale à cet anticorps, 2008. ,
Nomenclature internationale des différents types d'anticorps monoclonaux, Rev Med Liège, vol.64, pp.5-6, 2009. ,
Les anticorps monoclonaux thérapeutiques : une classe médicamenteuse majeure en pathologie digestive, HEPATO-GASTRO et Oncologie digestive, 2012. ,
Anticorps monoclonaux th??rapeutiques en canc??rologie, Pathologie Biologie, vol.60, issue.4, pp.223-228, 2012. ,
DOI : 10.1016/j.patbio.2012.05.008
has-sante.fr/portail/jcms/c_434715/fr/guide-d- analyse-de-la-litterature-et-gradation-des-recommandations ,
Toxicit??s orales des th??rapies cibl??es anticanc??reuses, M??decine Buccale Chirurgie Buccale, vol.21, issue.3, pp.149-155, 2015. ,
DOI : 10.1051/mbcb/2015025
Incidence of mucositis in patients with head and neck squamous cell carcinoma treated with radiotherapy plus cetuximab: a pilot study, M??decine Buccale Chirurgie Buccale, vol.18, issue.3 ,
DOI : 10.1051/mbcb/2012020
Lichenoid Mucosal Reaction to Rituximab, The Oncologist, vol.19, issue.10, pp.12-13, 2014. ,
DOI : 10.1634/theoncologist.2014-0169
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4200996
Characteristics of Oral Mucosal Events Related to Bevacizumab Treatment, The Oncologist, vol.17, issue.2, pp.274-278, 2012. ,
DOI : 10.1634/theoncologist.2011-0198
A Review on Bevacizumab and Surgical Wound Healing, Annals of Plastic Surgery, vol.62, issue.6, pp.707-716, 2009. ,
DOI : 10.1097/SAP.0b013e3181828141
Bevacizumab and Wound-Healing Complications, Annals of Plastic Surgery, vol.71, issue.4, pp.434-474, 2013. ,
DOI : 10.1097/SAP.0b013e31824e5e57
Osteonecrosis of the Jaw in the United States Food and Drug Administration's Adverse Event Reporting System (FAERS), Journal of Bone and Mineral Research, vol.2013, issue.2, pp.1-5, 2015. ,
DOI : 10.1002/jbmr.2693
Diagnosis and Management of Osteonecrosis of the Jaw: A Systematic Review and International Consensus, Journal of Bone and Mineral Research, vol.37, issue.9, pp.3-23, 2015. ,
DOI : 10.1016/S1359-6349(10)70055-
Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: a meta-analysis of seven randomized controlled trials, International Journal of Clinical Oncology, vol.28, issue.2, pp.403-410, 2014. ,
DOI : 10.1007/s10147-013-0561-6
Denosumab and osteonecrosis of the jaw. A systematic analysis of events reported in clinical trials, Clinical Oral Implants Research, vol.99, issue.3 ,
DOI : 10.1111/clr.12556
RANK ligand inhibition in bone metastatic cancer and risk of osteonecrosis of the jaw (ONJ): non bis in idem? Support Care Cancer, pp.2035-2040, 2011. ,
Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer, Breast Cancer Research and Treatment, vol.25, issue.18S, pp.181-188, 2010. ,
DOI : 10.1007/s10549-010-0866-3
URL : https://hal.archives-ouvertes.fr/hal-00535451
Clinical stady evaluating the effect of bevacizumab on the severity of zoledronic-acid releted osteonecrosis of the jaw in the cancer patients, Bon58, pp.103-107, 2014. ,
Osteonecrosis of the jaw: dental autcomes in metastatic breast cancer patients traited with bisphosphonates with/without bevacizumab. Cancer Breast, pp.252-259, 2011. ,
Osteonecrosis of the jaw in patients with cancer who received zoledronic acid and bevacizumab, The Journal of the American Dental Association, vol.142, issue.5, 2011. ,
DOI : 10.14219/jada.archive.2011.0220
Healing of osteonecrosis of the jaw (ONJ) after discontinuation of denosumab in a patient with bone metastases of colorectal cancer: A case report and hypothesis, Quintessence International. Oral medecine.V, vol.46, issue.7, 2015. ,
The relationship of denosumab pharmacology and osteonecrosis of the jaw. Medical management and pharmacologie update, p.114, 2012. ,
Denosumab-related osteonecrosis of the jaw: a cas reportand management based on pharmacokinetics. Oral Surg Oral Med Oral Pathol Oral Radiol, pp.1-6, 2015. ,
Denosumab-related osteonecrosis of the jaw, The Journal of the American Dental Association, vol.143, issue.9, 2012. ,
DOI : 10.14219/jada.archive.2012.0323
Denosumab and osteonecrosis of the jaws - the pharmacology, pathogenesis and a report of two cases, Australian Dental Journal, vol.72, issue.5 Suppl, pp.516-519, 2014. ,
DOI : 10.1111/adj.12217
Osteonecrosis of the jaw in patient with denosumab therapy, Int J Clin Exp Med, vol.7, issue.10, pp.3707-3709, 2014. ,
Osteonecrosis of the jaws induced by anti-RANK ligand therapy, British Journal of Oral and Maxillofacial Surgery, vol.48, issue.3, pp.221-223, 2010. ,
DOI : 10.1016/j.bjoms.2009.08.030
Osteonecrosis of the Jaw in a Patient on Denosumab, Journal of Oral and Maxillofacial Surgery, vol.68, issue.5, pp.959-963, 2012. ,
DOI : 10.1016/j.joms.2009.10.010
Denosumab osteonecrosis of the mandibule. A new entity? A cas raport Journal of cranio-maxillo-facial surgery, pp.4165-69, 2013. ,
Stage 0 Osteonecrosis of the Jaw in a Patient on Denosumab, Journal of Oral and Maxillofacial Surgery, vol.72, issue.4, pp.702-716, 2014. ,
DOI : 10.1016/j.joms.2013.09.008
Bevacizumab-related osteonecrosis of the mandible is a self-limiting disease process, Case Reports, vol.2012, issue.oct22 1, p.10, 2012. ,
DOI : 10.1136/bcr-2012-007284
A case report of bevacizumab-related osteonecrosis of the jaw: Old problem, new culprit, Oral Oncology, vol.48, issue.2, pp.2-3, 2012. ,
DOI : 10.1016/j.oraloncology.2011.07.030
Osteonecrosis of the mandible associated with bevacizumab therapy, Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, vol.115, issue.6, pp.32-36, 2013. ,
DOI : 10.1016/j.oooo.2013.02.001
Osteonecrosis of the Jaw Related to Bevacizumab, Journal of Clinical Oncology, vol.26, issue.24, 2008. ,
DOI : 10.1200/JCO.2007.15.5424
Osteonecrosis of the jaw in a patient with advaced non-small cell.lung cancer receiving bevacizumab, Arch.Bronconeumol, vol.2012, issue.6, pp.48-216 ,
Osteonecrosis of the mandible due to anti-angiogenic agent, bevacizumab, Oral and Maxillofacial Surgery, vol.11, issue.4, pp.303-306, 2013. ,
DOI : 10.1007/s10006-012-0379-9
American Association of Oral and Maxillofacial Surgeons American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw?2014 update, J Oral Maxillofac Surg, issue.10, pp.721938-56, 2014. ,
Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic, Journal of Oral and Maxillofacial Surgery, vol.61, issue.9, pp.1115-1122, 2003. ,
DOI : 10.1016/S0278-2391(03)00720-1
Infection and Medication-related Osteonecrosis of the Jaw, Journal of Dental Research, vol.15, issue.5966, pp.534-539, 2015. ,
DOI : 10.1038/nature01658
Effect of antiresorptive drugs on body turnover in the jaw: dénosumab compared with biphoshonates, British Journal of Oral and Maxillofacial Surgery, pp.52-308, 2014. ,
Pathophysiologie des métastases osseuses, Prog Urol, vol.13, pp.9-17, 2003. ,
Advances in Biology and Therapy of Multiple Myeloma, Hematology, vol.2003, issue.1, pp.248-278, 2003. ,
DOI : 10.1182/asheducation-2003.1.248